IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Betz, et al.

Patent No: 6,984,492) Int. Cl: C12Q 1/68

Issued: January 10, 2006) U.S. Cl.: 435/6

For: METHODS AND COMPOSITIONS FOR TREATING HERPES

INFECTIONS

CORRECTION OF ERROR IN PATENT

Under 37 CFR 1.322

Certificate of Correction Of Office Mistake

CERTIFICATE OF CORRECTION OFFICE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Assignee of the above-identified patent hereby requests that a Certificate of Correction be issued for this U.S. Patent. We enclose herewith Form PTO SB/44, which provides the changes as they should be listed.

The following reference was omitted from the U.S. Patent Documents at Paragraph 56: U.S. Pat. No. 6,307,028 B1, 10/2001, Lebing, et al., 530/390.1.

Assignee believes that the submission of the enclosed document, Form PTO – 1449, submitted January 8, 2004 supports the claim that the Patent Office is in error.

Respectfully submitted,

Carl B. Massey, Jr. Reg. No. 44,224

Attorney for Assignee

Date: () 2006

Womble Carlyle Sandridge & Rice, PLLC

P.O. Box 7037

Atlanta, Georgia 30357-0037

Telephone: (336) 721-3681 / Facsimile: (336) 726-8074

Docket: B185 1230.1

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO:	6,984,492

INVENTOR(S): Betz, et al.

DATED:

January 10, 2006

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Paragraph 56, the following cited reference was omitted from the U.S. Patent Documents Section:

U.S. Pat. No. 6,307,028 B1, 10/2001, Lebing, et al., 530/390.1

MAILING ADDRESS OF SENDER: Carl B. Massey, Jr., Esq. (Reg. No. 44,224) Womble Carlyle Sandridge & Rice, PLLC P.O. Box 7037 Atlanta, GA 30357-0037 PATENT NO.: 6,984,492
No of additional copies

Page 1

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

TO MED	1449	U.S. DEPARTM PATENT AND	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY DKT NO. B185 1230.1 APPLICANT			SERIAL NO. 10/656,781					
JAN 0 8 2004	INFORMATION DISCLOSURE						Ulrich Betz, et al. FILING DATE GROUP								
STATEMENT BY APPLICANT						09/05/0	3	1614							
			211	Dateni	T DOCUMENTS	N									
EXAMINER		DOCUMENT	CL.		SUBCL.		EH D	IG DATE							
INITIAL	n	NO.			NAME			L SOBCE.		IF APPROP.					
	PI	U.S. Pat. No. 6,307,028 B1	10/23/01	Lebing,	Lebing, et al.		530	390.1							
							 	-							
·	<u> </u>														
FOREIGN PATENT DOCUMENTS															
		DOCUMENT N	DOCUMENT NO. DAT		E COUNTRY		CL.	SUBCL T		TRANSLATION					
								<u> </u> -		ÆS	NO				
							 								
							-								
	ļ														
	 														
	 								+-						
							ll								
OTHER DOCUMENTS (Incl. Author, Title, Date, Pertinent pages, etc.) D1 Elrich, K.S., et al., "Prevention and Treatment of Experimental Hernes Simpley Virus French 1997															
1		ruman iminune	Elrich, K.S., et al., "Prevention and Treatment of Experimental Herpes Simplex Virus Encephalitis with Human Immune Serum Globulin," Antimicrobial Agents and Chemotherapy, 31(7): 1006-1009 (1987).												
	D2	Cornea, 20(5): 4	Epstein, S.P., et al., "Efficacy of Polyclonal Antibodies for Treatment of Ocular Herpes Simplex Infection," Cornea, 20(5): 495-500 (2001).												
	D3	LeBlanc, R.A., e	LeBlanc, R.A., et al., "Treatment of HSV-1 Infection with Immunoglobulin or Acyclovir: Comparison of												
	D4	Raizman, M.B. a	Their Effects on Viral Spread, Latency, and Reactivation," Virology, 262(1): 230-236 (1999). Raizman, M.B, and C.S. Foster, "Passive transfer of anti-HSV-1 IgG protects against stromal keratitis in												
		inice, Current E	1 mice, Current Eye Research, 7(8): 823-829 (1988)												
	D5	Ritchie, M.H., et	Ritchie, M.H., et al., "Passive Transfer of Anti-Hemes Simpley Virus Type 2 Manager 1 and D. L. L.												
\cup		Induced Stromal	Antibodies Protect Against Herpes Simplex Virus Type 1-Induced but Not Herpes Simplex Virus Type 2-Induced Stromal Keratitis," <i>Investigative Opthalmology & Visual Science</i> , 34(8): 2460-2468 (1993).												
					- cp	c 7 isuai b	cience, 54(6). 2400	-2408	(1993)	<u>. </u>				
						·									
EXAMINER	·				DATE	CONSID	ERED	//	· · ·	-					
								6/							
EXAMINER: I in conformance	Initial e and r	if citation considered, not considered. Includ	whether or no e copy of this	ot citation form with	is in conformance n next communica	with MI	PEP 609; dr oplicant.	aw line t	hroug	h citati	on if not				
							-				ł				